Although both BRAF and CRAF are expressed and active in melanoma signaling processes, only BRAF shows a high mutation frequency (approximately 50% of melanomas), whereas CRAF mutations are rare and so far have not been demonstrated to generate an alternative activated oncogene. The gene discussed is BRAF; the disease is melanoma.